• 

  Decision on Emergency Use Listing of Covaxin likely in August first week: WHO

  India | July 10, 2021 16:33 IST

  Speaking at a webinar organised by the Centre for Science and Environment (CSE) on Friday, Soumya Swaminathan said the WHO is reviewing Covaxin as its manufacturer Bharat Biotech is now uploading its entire data on the health body’s portal.

• 

  Bharat Biotech concludes phase 3 Covaxin trial, claims 77.8% efficacy against COVID 19

  India | July 03, 2021 8:37 IST

  Covaxin gives 77.8 per cent efficacy against COVID 19, and 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant

• 

  Brazil suspends Bharat Biotech's Covaxin order over graft allegations

  India | June 30, 2021 14:12 IST

  Announcing the Brazil government's decision, its Health Ministry said in a statement that "with the recommendation of the Office of the Comptroller General of the Union, the Ministry of Health temporarily suspended the contract for the purchase of Covid-19 vaccine from Covaxin this Tuesday (29)."

• 

  'Covaxin pricing clearly established': Bharat Biotech clarifies on Brazil deal row

  India | June 30, 2021 12:28 IST

  The Covaxin contract to Brazil had landed in controversy after the South American country's Attorney General reportedly launched a probe into the deal.

• 

  Brazil to suspend Covaxin deal with Bharat Biotech over allegations of irregularities by President

  World | June 30, 2021 8:21 IST

  Brazil had in February signed a deal with Bharat Biotech to procure 20 million doses of Covaxin for USD 324 million.

• 

  Bharat Biotech chairman Krishna Ella given central security cover

  India | June 29, 2021 21:03 IST

  The officials said Krishna Ella was provided the security cover of Central Industrial Security Force (CISF) armed commandos sometime ago given his current profile of spearheading the production of life-saving vaccines and other medical essentials.

• 

  Over 1.45 crore vaccine doses available with states: Centre

  India | June 26, 2021 11:51 IST

  More than 1.45 crore COVID-19 vaccine doses are still available with states and union territories and over 19,10,650 jabs are in the pipeline.

• 

  Bharat Biotech, WHO meet for 'pre-submission' of Covaxin's Emergency Use Listing

  India | June 24, 2021 12:11 IST

  As per WHO guidelines, Emergency Use Listing (EUL) is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies. It has already submitted 90 per cent of documents to WHO for obtaining EUL for Covaxin

• 

  Covaxin shows 77.8% efficacy in phase 3 trial, likely to get clearance today

  India | June 22, 2021 17:52 IST

  Hyderabad-based Bharat Biotech has been facing tough questions over the delay in announcing its phase 3 trial data of the vaccine.

• 

  Bharat Biotech submits Covaxin's Phase III trial data to DCGI: Sources

  India | June 22, 2021 9:32 IST

  Bharat Biotech's Covaxin is one of the three vaccines which are currently being used in India. The phase III data of its vaccine have been questioned various times and that is what makes the data crucial which will ascertain the efficacy of the vaccine.

• 

  Bharat Biotech's pre-submission meeting for Covaxin EUL with WHO on June 23

  India | June 18, 2021 15:45 IST

  Bharat Biotech had said last month that it expects approval for its COVID-19 vaccine Covaxin from the World Health Organisation for Emergency Use Listing (EUL) during July-September.

Advertisement
• 

  Aaj Ki Baat: Why rumour was spread on social media that calf serum was used in making of Covaxin vaccine

  Aaj Ki Baat | June 16, 2021 22:48 IST

  The Union Health Ministry has said that some social media posts have distorted facts that the indigenously manufactured Covaxine contains the serum of a newborn calf. The Health Ministry said that the serum of the newborn calf is used only for the preparation and development of Vero cells

• 

  Rs 150 per Covaxin dose to Centre not sustainable in long run: Bharat Biotech

  India | June 15, 2021 15:24 IST

  The supply price of Bharat Biotech''s COVID-19 vaccine Covaxin to the central government at Rs 150 per dose is not sustainable in the long run, the vaccine maker said on Tuesday.

• 

  AIIMS Delhi to start Covaxin trial for children aged 6-12 from today

  India | June 15, 2021 8:35 IST

  The recruitment for the clinical trial Bharat Biotech's vaccine Covaxin, among children in the age group of 6-12 years will begin at the AIIMS today.

• 

  Covaxin's phase 3 results soons, says Bharat Biotech

  India | June 13, 2021 9:11 IST

  Bharat Biotech on Saturday said scientific standards and commitment of the indigenously-developed COVID-19 vaccine Covaxin are transparent.

• 

  Covaxin manufacturer Bharat Biotech to carry out clinical trials in US

  India | June 12, 2021 17:30 IST

  In a setback to Bharat Biotech's COVID-19 vaccine Covaxin, the US Food and Drug Administration has "recommended" Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data, nixinghopes of Emergency Use Authorisation.

• 

  Covaxin phase 3 full trial data to be made public in July: Bharat Biotech

  India | June 09, 2021 18:48 IST

  Covaxin phase 3 full trial results will be made public in July, Bharat Biotech informed on Wendesday. Covaxin is one of the three vaccines other than Oxford's Covishield and Russia's Sputnik V, that are being administered in India.

• 

  Covaxin protects against Delta, Beta variants of COVID-19, says study

  India | June 09, 2021 13:26 IST

  The Delta variant (B.1.617.2) was first found in India and is the dominant strain in the country, the Beta variant (B.1.351) was first discovered in South Africa.

• 

  Vaccination in Rajasthan halted since May 31: State Health Minister

  News | June 08, 2021 20:29 IST

  Rajasthan Health Minister Dr Raghu Sharma informed that vaccination in the state has been halted since May 31. He further said that next batch of vaccines will arrive on June 09.

• 

  Delhi: AIIMS to start screening children for Covaxin trials from today

  India | June 07, 2021 9:33 IST

  AIIMS in Delhi will begin screening of children aged 2 to 18 years for Covaxin trials from today.